Perspectives

All oncologists know how anxiously cancer patients look forward to the availability in clinical practice of drugs that have yielded positive results in the registration trials.

Focus on

Medication review and deprescribingThe increase in life expectancy and the growing availability of effective drugs for the management of chronic diseases are leading to an increase in the number of patients, suffering of multimorbidity, in polypharmacotherapy (regular intake of at least five...

Columns

Drugs & Elderly
In recent years, the concept of deprescribing has been introduced, based on the reduction of the number of drugs taken in order to optimize the risk-benefit ratio of polypharmacy taking into account the goals of treatment and the preferences of the patient; however, the available intervention...

From regulatory agencies

17 November 2026 FDA 13 November 2026 FDA
12 November 2026 FDA 10 November 2026 FDA
10 November 2026 FDA 09 November 2026 FDA
09 November 2026 FDA 09 November 2026 FDA
09 November 2026 FDA 06 November 2026 FDA
Zadig3